This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Introduction: Evaluating Clinical Trial Data From Schizophrenia Research

Carol A. Tamminga, MD

Published: August 1, 2001

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Clinical research trials are vital to the effective and safe use of new drugs. When conducted competently and analyzed correctly, clinical trials yieldvaluable information that will ultimately be disseminated to and interpreted by physicians in clinical practice. Therefore, it is important to understand the issues raised and the questions answered by clinical trials. To that end, a group of distinguished researchers held a symposium to discuss the issues influencing clinical trial data: hypotheses and hypothesis testing, patient selection and dropout rates, study design, outcome measures, dose selection and comparator drugs, statistical analyses, and interpretations and conclusions.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: